3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization.

Autor: Grisanti F; Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain. fabianagrisanti@gmail.com., Prieto E; Department of Medical Physics, Clínica Universidad de Navarra, Pamplona, Spain., Bastidas JF; Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain., Sancho L; Department of Nuclear Medicine, Clínica Universidad de Navarra, Madrid, Spain., Rodrigo P; Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain., Beorlegui C; Department of Health, Government of Navarre, Pamplona, Spain., Iñarrairaegui M; Liver Unit, Clínica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain., Bilbao JI; Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain., Sangro B; Liver Unit, Clínica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain., Rodríguez-Fraile M; Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Sep; Vol. 48 (10), pp. 3048-3057. Date of Electronic Publication: 2021 Mar 05.
DOI: 10.1007/s00259-021-05272-9
Abstrakt: Introduction: Volume changes induced by selective internal radiation therapy (SIRT) may increase the possibility of tumor resection in patients with insufficient future liver remnant (FLR). The aim was to identify dosimetric and clinical parameters associated with contralateral hepatic hypertrophy after lobar/extended lobar SIRT with 90 Y-resin microspheres.
Materials and Methods: Patients underwent 90 Y PET/CT after lobar or extended lobar (right + segment IV) SIRT. 90 Y voxel dosimetry was retrospectively performed (PLANET Dose; DOSIsoft SA). Mean absorbed doses to tumoral/non-tumoral-treated volumes (NTL) and dose-volume histograms were extracted. Clinical variables were collected. Patients were stratified by FLR at baseline (T0-FLR): < 30% (would require hypertrophy) and ≥ 30%. Changes in volume of the treated, non-treated liver, and FLR were calculated at < 2 (T1), 2-5 (T2), and 6-12 months (T3) post-SIRT. Univariable and multivariable regression analyses were performed to identify predictors of atrophy, hypertrophy, and increase in FLR. The best cut-off value to predict an increase of FLR to ≥ 40% was defined using ROC analysis.
Results: Fifty-six patients were studied; most had primary liver tumors (71.4%), 40.4% had cirrhosis, and 39.3% had been previously treated with chemotherapy. FLR in patients with T0-FLR < 30% increased progressively (T0: 25.2%; T1: 32.7%; T2: 38.1%; T3: 44.7%). No dosimetric parameter predicted atrophy. Both NTL-Dmean and NTL-V30 (fraction of NTL exposed to ≥ 30 Gy) were predictive of increase in FLR in patients with T0 FLR < 30%, the latter also in the total cohort of patients. Hypertrophy was not significantly associated with tumor dose or tumor size. When ≥ 49% of NTL received ≥ 30 Gy, FLR increased to ≥ 40% (accuracy: 76.4% in all patients and 80.95% in T0-FLR < 30% patients).
Conclusion: NTL-Dmean and NTL exposed to ≥ 30 Gy (NTL-V30) were most significantly associated with increase in FLR (particularly among patients with T0-FLR < 30%). When half of NTL received ≥ 30 Gy, FLR increased to ≥ 40%, with higher accuracy among patients with T0-FLR < 30%.
(© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: